IPO registrations (S-1, F-1) · Registrants
Transcode Therapeutics, Inc.
- SEC CIK
- 1829635 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-02-26, last 2026-05-01; 8 initial registrations, 12 amendments
- Outcome
- Final prospectus filed 2021-07-09; declared effective 2021-07-08; withdrawal requested 2022-12-06
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 6 LIBERTY SQUARE, #2382, Boston, MA 02109
- EIN
- 81-1065054
- Ticker
- RNAZ (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Transcode Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $4.00 per share (424B4 filed 2021-07-09, an initial public offering)
- Shares sold
- 6,250,000
- Gross proceeds
- $25,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RNAZ
- Lead underwriters
- ThinkEquity; ThinkEquity, a division of Fordham Financial Management, Inc (6,250,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: TRANSCODE THERAPEUTICS, INC. Fuzzy (name and state)
- Federal award recipient: TRANSCODE THERAPEUTICS, INC. Fuzzy (name and state)
- Form D issuer: Transcode Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Transcode Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 35
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-02-26 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-21-029169 ↗ |
| 2021-03-24 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-21-040777 ↗ |
| 2021-04-08 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-21-047837 ↗ |
| 2021-04-16 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-21-050962 ↗ |
| 2021-05-03 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-21-059902 ↗ |
| 2021-06-02 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-21-075821 ↗ |
| 2021-07-08 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-21-002678 ↗ |
| 2021-07-09 | 424B4 | 424B4 (final prospectus) | Transcode Therapeutics, Inc. | 0001104659-21-090708 ↗ |
| 2022-11-28 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-22-122190 ↗ |
| 2022-11-30 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-22-123017 ↗ |
| 2022-12-06 | RW | RW (withdrawal request) | Transcode Therapeutics, Inc. | 0001104659-22-124886 ↗ |
| 2022-12-16 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-22-003573 ↗ |
| 2023-02-01 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-23-009249 ↗ |
| 2023-02-14 | RW | RW (withdrawal request) | Transcode Therapeutics, Inc. | 0001104659-23-021682 ↗ |
| 2023-05-19 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-23-062676 ↗ |
| 2023-06-05 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-23-068097 ↗ |
| 2023-06-06 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-23-068436 ↗ |
| 2023-06-06 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-23-001646 ↗ |
| 2023-06-07 | 424B4 | 424B4 (final prospectus) | Transcode Therapeutics, Inc. | 0001104659-23-068986 ↗ |
| 2023-08-29 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-23-096557 ↗ |
| 2023-09-11 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-23-099406 ↗ |
| 2023-09-25 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-23-103270 ↗ |
| 2023-09-25 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-23-002739 ↗ |
| 2023-09-27 | 424B4 | 424B4 (final prospectus) | Transcode Therapeutics, Inc. | 0001104659-23-104356 ↗ |
| 2024-01-11 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-24-003172 ↗ |
| 2024-01-17 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-24-004279 ↗ |
| 2024-01-18 | S-1/A | S-1/A (amendment) | Transcode Therapeutics, Inc. | 0001104659-24-004721 ↗ |
| 2024-01-18 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-24-000151 ↗ |
| 2024-01-22 | 424B4 | 424B4 (final prospectus) | Transcode Therapeutics, Inc. | 0001104659-24-005323 ↗ |
| 2024-12-06 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-24-126354 ↗ |
| 2024-12-17 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-24-003810 ↗ |
| 2025-12-22 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-25-003889 ↗ |
| 2026-05-01 | S-1 | S-1 (registration) | Transcode Therapeutics, Inc. | 0001104659-26-053289 ↗ |
| 2026-05-19 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-26-001703 ↗ |
| 2026-05-19 | EFFECT | EFFECT (declared effective) | Transcode Therapeutics, Inc. | 9999999995-26-001704 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-02 | S-1/A | registration statement | $4.00 | 6,250,000 | $25,000,000 | Nasdaq RNAZ | 2 | primary document; price sentence, shares headline, proceeds computed, underwriting table 1, cover names 1 | document ↗ | |
| 2021-07-09 | 424B4 | final prospectus | $4.00 | 6,250,000 | $25,000,000 | Nasdaq RNAZ | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 1, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Calais Philippe | Director | 5 | 2021–2024 | ||
| Dudley Robert Michael | Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer | 10 | 2021–2023 | |
| Fitzgerald Thomas A | Director,Officer | Chief Financial Officer; Interim CEO, CFO; VP, Chief Financial Officer | 9 | 2021–2026 | |
| Manting Erik | Director | 5 | 2021–2024 | ||
| Marquet Magda | Director | 5 | 2021–2024 | ||
| Medarova Zdravka | Officer,TenPercentOwner; TenPercentOwner | Chief Technology Officer | 3 | 2021–2022 | |
| Moore Anna | TenPercentOwner | 1 | 2021 | ||
| CZEREPAK ELIZABETH | Director | 1 | 2025 | ||
| STOVER JACK E | Director | 1 | 2025 | ||
| CK Life Sciences Intl (Holdings) Inc | TenPercentOwner | 2 | 2026 | ||
| DEFJ, LLC | TenPercentOwner | 2 | 2026 | ||
| Tattory John A | Officer | Interim CFO | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-12-12 | Transcode Therapeutics, Inc. | Biotechnology | $8,000,000 | $8,000,000 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | TRANSCODE THERAPEUTICS, INC. | MA | State business registries | name and state |
| Federal award recipient | TRANSCODE THERAPEUTICS, INC. | MA | Federal spending (USAspending) | name and state |
| Form D issuer | Transcode Therapeutics, Inc. | MA | Form D private offerings | CIK (EXACT) |
| SEC filer | Transcode Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | TransCode Therapeutics, Inc. | MA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.